Bioventus outlines $600M-$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics
Source: SeekingAlpha
2026-03-05 10:26:46 ET
More on Bioventus
- Bioventus Inc. (BVS) Q4 2025 Earnings Call Transcript
- Bioventus Inc. 2025 Q4 - Results - Earnings Call Presentation
- Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Bioventus Non-GAAP EPS of $0.24 beats by $0.02, revenue of $157.9M beats by $2.95M
- Seeking Alpha’s Quant Rating on Bioventus
Read the full article on Seeking Alpha
For further details see:
Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics
Bioventus Inc.
NASDAQ: BVS
BVS Trading
0.0% G/L:
$8.34 Last:
191,041 Volume:
$8.40 Open:
BVS Latest News
BVS Stock Data
$668,312,953
30,456,863
0.21%
45
N/A
Medical Equipment & Supplies
Healthcare
US
Durham
